We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

5Effect of Termination Sample Clauses

5Effect of Termination. 20.5.1. Subject to Sections 20.5.4 and 20.5.5 below, termination of this Agreement will not limit either Party from pursuing any other remedies available to it under any agreement and/or applicable law, and termination or expiration of this Agreement, from whatever cause arising, shall be without prejudice to the rights of the Parties accrued under this Agreement up to the time of termination.
5Effect of Termination. Termination of the Framework Terms will automatically terminate all Order Forms governed by the Framework Terms. Upon any expiration or termination: (a) Customer will no longer have any right to use the Product. (b) Upon Customer’s request, Provider will delete Customer Content within 60 days. (c) Each Recipient will return or destroy Discloser’s Confidential Information in its possession or control. (d) Provider will submit a final bill or invoice for all outstanding Fees accrued before termination and Customer will pay the invoice according to Section 4 (Payment & Taxes).
5Effect of Termination. Upon the termination of this Agreement, you shall immediately cease to represent yourself as Cisco Certified. 5LIMITATION OF LIABILITY IN NO EVENT SHALL CISCO BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, OF ANY KIND REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, OR OTHERWISE, EVEN IF CISCO HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION WILL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN. 6PRIVACY AND DELIVERY OF CERTIFICATION INFORMATION TO THIRD PARTIES Cisco is a global company and may share your personal information with other Cisco offices or affiliates in the country in which you reside and in other countries. In addition, Xxxxx uses third party vendors, such as testing centers, and may share your personal information with such vendors, if necessary, for delivery or administration of the Programs. To share your personal information, Cisco may transfer your information outside the European Union. All parties with which Cisco shares your personal information are governed by this Agreement or are bound by appropriate confidentiality and data transfer agreements. Your personal information is not shared outside Cisco and its authorized third party vendors without your permission, except under the following conditions: Cisco often receives requests from third parties, particularly employers, to verify an individual's Certification status. Cisco may, but has no obligation to, provide such information about your Certification status to others. In such situations, Cisco will provide the information in its possession and will depend on you to periodically verify that such information is correct. Cisco shall have no liability for providing incorrect information to third parties in response to a proper request to verify your Certification status. Such processing may include transfer of information outside the European Union. Cisco may be obligated to disclose your
5Effect of TerminationUpon termination in accordance with this Section, and upon expiration of the Subscription Term, You shall immediately cease use of and access to the applicable Service and any Non-Celonis Application. 13.5 終了の効果 本条に基づく終了時、およびサブスクリプション期間の終了時、お客様は、該当するサービスおよび非Celonisアプリケーションの使用およびアクセスを直ちに停止するものとします。
5Effect of Termination. On the effective date of termination or expiration of the Term of this Agreement (including any applicable Wind-Down Period) DRM Provider shall promptly cease all activities contemplated under this Agreement and cease to offer the DRM for use in the Ecosystem. Within thirty (30) days after the termination or expiration of the Term of this Agreement (including any applicable Wind-Down Period), each Party shall, and shall cause its Authorized Recipients to, return all Confidential Information to the other Party or, at the other Party’s option, destroy all such information in its or their possession, retaining no copies thereof, and provide to the other Party a written certification of such destruction signed by a senior officer of the applicable Person, provided, however, that neither Party shall be obligated under this Section 9.5 to return or destroy such Confidential Information that it received, and is entitled to then have, under another DECE agreement.
5Effect of Termination. Executive agrees that should Executive’s employment be terminated for any reason, Executive shall be deemed to have resigned from any and all positions with the Company, including, but not limited to, a position on the board of directors of the Company and all positions with any and all subsidiaries and Affiliates of the Company.
5Effect of Termination. 19.5.1. Subject to Sections 19.5.419.5.4 and 19.5.519.5.5 below, termination of this Agreement will not limit either Party from pursuing any other remedies available to it under any agreement and/or applicable law, and termination or expiration of this Agreement, from whatever cause arising, shall be without prejudice to the rights of the Parties accrued under this Agreement up to the time of termination. 19.5.2. The provisions of this Agreement which expressly or by their nature are required to survive termination of this Agreement (including but without limitation provisions regarding Warranty, Intellectual Property and Liability) shall survive the expiration or termination of this Agreement. 19.5.3. Upon receipt of any termination notice, Supplier shall, take all required steps and actions to: (i) Cease all Works according to the IPM's instructions; and (ii) Transfer to ISR all its rights under all warranties extended by its suppliers.
5Effect of Termination. 48 Article IX INDEMNIFICATION...............................................................................................................................49 9.1Survival of Representations, Warranties and Covenants................................................................49 9.2Indemnification........................................................................................................................50 9.3Limitations on Liability..............................................................................................................51 9.4Indemnification Procedures........................................................................................................52 9.5Exclusive Remedy....................................................................................................................53 9.6Characterization of Indemnity Payments......................................................................................54 Article X MISCELLANEOUS...................................................................................................................................54 10.1Notices......................................................................................................................................54 10.2Amendments and Waivers..........................................................................................................55 10.3Expenses................................................................................................................................55 10.4Successors and Assigns............................................................................................................55 10.5Governing Law........................................................................................................................56
5Effect of Termination. In the event of termination of this Agreement, for any reason (including, without limitation, completion of the Clinical Study), the Lead Investigator shall cease providing Study Samples to Laboratory; provided, that, to the extent permitted by applicable law and regulations and any relevant informed consent document, Laboratory shall have the continued right to use the Study Samples in its possession in connection with blood-based, cell-free circulating biomarkers on the Laboratory’s proprietary Nu.QTM platform including for additional indications. Within one hundred eighty (180) days from the effective date of any termination (including, without limitation, completion of the Clinical Study), the Lead Investigator and Lead Institution shall obtain from the Research Institutions and Principal Investigators all available unblinded patient data collected in connection with the Clinical Study including without limitation Annual Reports and the final written report described in Section 5.4 above, and except as otherwise provided herein, any materials and Confidential Information provided by Laboratory or Lead Institution for the conduct of the Clinical Study; provided, however that one (1) copy of Confidential Information may be retained for archival purposes. If Lead Institution or Laboratory terminates this Agreement for any reason, Lead Institution will provide, and Laboratory will have the perpetual right to use, all available unblinded patient data for the Study Samples already paid for and received by Laboratory on the completion of the Clinical Study. If the Clinical Study is terminated for any reason, Lead Institution will provide, and Laboratory will have the perpetual right to use, all available unblinded patient data for the Study Samples already provided to Laboratory immediately upon termination and completion of the analysis by relevant EDRN components (e.g. Data Management and Coordinating Center) of the Clinical Study. For avoidance of doubt, the patient data included in the Case Report Forms to the Protocol shall be made available to Laboratory under this Section 11.5, which shall include, without limitation, (a) patient conditions (i.e. colorectal cancer, high risk adenoma), (b) age, (c) sex, (d) any other history, and (e) any other diseases. In addition, Lead Institution agrees to, and will ensure that all Research Institutions, hold unblinded patient data for at least three (3) months after the completion of the Clinical Study.
5Effect of Termination. Upon the termination of this Agreement, you shall immediately cease to represent yourself as Cisco Certified. 5LIMITATION OF LIABILITY IN NO EVENT SHALL CISCO BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, OF ANY KIND REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, OR OTHERWISE, EVEN IF CISCO HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION WILL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN. 6PRIVACY AND DELIVERY OF CERTIFICATION INFORMATION TO THIRD